Ceva, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 9, 2026, reporting financial results for the three and nine months ended on that date.
ZipRecruiter, Inc. filed a quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission covering the fiscal quarter ended September 30, 2026, disclosing share counts as of November 2, 2026, and providing financial statements, management discussion, and an updated risk factor section.
Zentalis Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 9, 2026, disclosing financial results, operational updates, and risk factors for the quarter.
Kemper Corporation filed a Form 8-K on November 9, 2026, announcing the release of its financial results for the third quarter of 2026 along with the availability of an investor supplement and earnings call presentation on its website.
ADC Therapeutics SA (NYSE:ADCT) filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 9, 2026, covering the company's financial condition and operations through the third quarter.
Redwood Trust, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the Securities and Exchange Commission on November 9, 2026, reporting a net loss of $45.5 million for the third quarter and total assets of approximately $30.4 billion.
Clearway Energy, Inc. filed its quarterly report on Form 10-Q with the SEC on November 9, 2026, covering the period ended September 30, 2026, and disclosing share counts, debt structure, and a completed solar portfolio acquisition.
MARA Holdings, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 9, 2026, reporting a net income of $632.071 million for the third quarter alongside a net loss of $1.241643 billion for the nine months …
Occidental Petroleum Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 9, 2026, reporting continued operations following the January 2026 close of its OxyChem divestiture.
Attovia Therapeutics, Inc. filed a Form 8-K on November 9, 2026, disclosing positive topline 12-week results from its Phase 1b study of ATTO-1310 in patients with chronic pruritus and high-itch atopic dermatitis, alongside a report of its third-quarter 2026 financial results.